Cite
HARVARD Citation
Folschweiller, N. et al. (2022). Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. Lancet infectious diseases. 22 (7), pp. 1062-1075. [Online].